Fentanyl and Esketamine: Interaction Details
- Esketamine
- Spravato
- Fentanyl
- AbstralActiqFentora +3 more
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS
Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page
- Dr. Brian Staiger, PharmD, BCPS, is a clinical pharmacist and pharmacotherapy specialist.
- AI-assisted, written
- AI is used only to summarize verified clinical information, never the open internet.
- Editorial policy
- How we build our interaction pages →
- Our AI policy →
A close look at the Fentanyl and Esketamine interaction:
Esketamine
- Spravato
We don't have a drug information page for Esketamine yet. Have a question about Esketamine? Ask a pharmacist, free →
Fentanyl
- Abstral
- Actiq
- Fentora
- Onsolis
- Subsys
- Ionsys
What Happens When You Take Fentanyl With Esketamine
What can happen when they are taken together (rated Major)
Increased fentaNYL exposure and an increased risk of profound , , , coma and death
Interaction Deep Dive
A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →
When fentaNYL is taken together with a drug that both depresses the and inhibits , fentaNYL exposure can rise, leading to stronger or longer-lasting effects. This is especially likely if the is introduced after the fentaNYL dose has already been stabilized.
The combination can also produce CNS effects, including respiratory depression, hypotension, profound sedation, coma, or death. prescribing should be limited to patients for whom other treatment options are not adequate.
When a CNS depressant is prescribed alongside fentaNYL, use the lowest effective dosages for the shortest possible duration of combined use, and titrate according to clinical response. If the combination cannot be avoided, consider lowering the fentaNYL dosage until drug effects are stable, and assess patients frequently for respiratory depression and sedation.
Once a CYP3A4 inhibitor is stopped, its effect wanes and fentaNYL exposure falls, which can reduce opioid or trigger a withdrawal syndrome in patients who have become physically dependent on fentaNYL. If a CYP3A4 inhibitor is discontinued, consider raising the fentaNYL dosage until stable drug effects are reached.
Patients and caregivers should be informed about, and educated on, the signs and symptoms of respiratory depression. Patients should be monitored for opioid withdrawal, respiratory depression, sedation, and hypotension. For postoperative analgesia, begin with a lower dose of fentaNYL injection, and keep fluids and other measures on hand to treat possible hypotension.3
The Fentanyl and Esketamine Interaction, Explained
Taking esketamine (Spravato) with fentanyl can be risky because both slow down your brain and breathing. Esketamine can make you sleepy, dizzy, and lower your blood pressure. Fentanyl is a strong pain medicine with the same kinds of effects. Together they can cause very deep sleepiness, slow or shallow breathing, and in the worst cases coma. The database also lists a possible effect on how your body clears fentanyl, which could leave more of it in your system.
This is a well-established concern, but it can be managed. Keep taking your medicines as prescribed and tell your pharmacist and prescriber about both. They may adjust your fentanyl dose, watch you more closely, and teach you and your family what warning signs to look for, such as extreme drowsiness or trouble breathing.
Esketamine + fentanyl: and , plus . The database lists of -mediated fentanyl as a probable mechanism, which would raise fentanyl exposure. Fentanyl is active itself (not a ), so reduced means increased and prolonged effect. Onset unspecified; evidence: established; severity: major.
- Reserve co-prescribing for patients with inadequate alternatives; use the lowest effective doses for the shortest duration and titrate to response.
- Consider fentanyl dose reduction until effects stabilize.
- Monitor frequently for , respiratory depression, hypotension, and withdrawal.
- If a CYP3A4 is stopped, fentanyl exposure falls (reduced or withdrawal), so consider a dose increase to restore stable effect.
- Counsel patients and caregivers on signs of respiratory depression. For postoperative use, start with a lower fentanyl dose and have fluids available for hypotension.
See the 7 references behind this explanation ↓
From the HelloPharmacist Pharmacy Team
AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .
How we build these pages · How we use AI · Our editorial policy
Why Fentanyl and Esketamine Interact
The likely mechanism
of -mediated of fentaNYL;
How to Manage the Fentanyl and Esketamine Interaction
Do not stop or change either medicine on your own. Your care team can manage this combination, and they usually reserve it for people who do not have good alternatives.
- Your prescriber may use the lowest effective doses for the shortest time, and your fentanyl dose may need to be adjusted and individualized by your care team.
- Your team may monitor you more closely for sleepiness, slow breathing, low blood pressure, and withdrawal symptoms.
- Ask your pharmacist to review all your medicines, since stopping or starting certain ones can change how much fentanyl is in your body.
- Make sure family or caregivers know the warning signs of slowed breathing and when to get urgent help.
Management is individual — confirm any change with your pharmacist or prescriber.
Questions for Your Pharmacist
- Does my dose of Fentanyl or Esketamine need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there another option that avoids this interaction?
Literature Reports
6 reports from the published literature. Each one is headed by the title of the published study it comes from.
What these reports are. Short summaries of published evidence on this combination: clinical studies, case reports and, at times, the FDA prescribing information for one of the drugs. They support this interaction, but it does not rest on them alone. It can also rest on prescribing information not summarized here, or on what is expected from how these two drugs, and others in their drug classes, are known to work.
-
Report 1 · Study title
Prescribing information: DIFLUCAN oral tablets, suspension, fluconazole oral tablets, suspension
A single fatal case of a possible fentaNYL-fluconazole interaction has been reported, and the author concluded that the patient died of fentaNYL intoxication. In addition, a randomized crossover study in 12 healthy volunteers showed that fluconazole significantly delayed the of fentaNYL. Higher fentaNYL concentrations may result in .7
-
Report 2 · Study title
Ritonavir's role in reducing fentanyl clearance and prolonging its half-life
Twelve healthy volunteers were given either placebo or oral ritonavir three times daily for 3 days, and on the second day a fentaNYL dose of 5 mcg/kg IV was administered after the second ritonavir dose. Naloxone was given before and together with the fentaNYL dose to prevent the sedative and respiratory depressant effects of fentaNYL.
One subject withdrew from the study before receiving fentaNYL. Among the 11 remaining participants, ritonavir reduced the plasma of fentaNYL by 67% (from 15.6 to 5.2 mL/min/kg).
Compared with placebo, the of fentaNYL rose from 9.4 hours to 20.1 hours after ritonavir, and the area under the concentration-time curve () rose by 174% (from 6.6 to 18.1 ng/mL/hr). Ritonavir is considered likely to affect the elimination of transdermally administered fentaNYL in a similar way.4
-
Report 3 · Study title
Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl
In an open, randomized, crossover study, giving fluconazole with a single IV dose of fentaNYL lowered the mean plasma of fentaNYL by 16%. Twelve healthy volunteers received a single IV dose of fentaNYL 5 mcg/kg, either alone (control phase) or 1 hour after the last fluconazole dose on day 2 (400 mg orally once daily on day 1, then 200 mg orally once daily on day 2).
Naloxone was given before and with the fentaNYL dose to prevent the sedative and respiratory depressant effects of fentaNYL. All 12 subjects completed the study.
In the fluconazole phase, mean plasma clearance was 16% lower than in the control phase (range, -34% to 53%; p less than 0.05). The fentaNYL showed a nonsignificant increase (fluconazole phase, 7.7 +/- 2.3 nanograms (ng) x hr/mL vs control phase 6.1 +/- 1.1 ng x hr/mL), whereas the inactive norfentaNYL decreased markedly (fluconazole phase, 0.8 +/- 0.7 ng x hr/mL vs control phase, 1.8 +/- 1.1 ng x hr/mL).
The ratio of norfentaNYL AUC to fentaNYL AUC was significantly lower in the fluconazole phase than in the control phase (AUC ratio, 0.1 +/- 0.1 vs 0.3 +/- 0.2). Mean of fentaNYL was the same in both phases. The altered fentaNYL clearance seemed to result from of -mediated N-dealkylation of fentaNYL to norfentaNYL.5
-
Report 4 · Study title
Possible fluconazole-fentanyl interaction-a case report
A 46-year-old man treated with transdermal fentaNYL died after concurrent treatment with fluconazole. He had oral pain from radiation therapy for tonsillar cancer and was treated with a fentaNYL 100 mcg/hr transdermal patch.
Over the following 1.5 months, the fentaNYL dose was raised to 150 mcg/hr. medications included morphine 10 mg orally once daily, diclofenac 50 mg orally 3 times daily, paracetamol 1000 mg orally 3 times daily, oxazepam 15 mg orally twice daily, zolpidem 5 mg orally nightly, nystatin (100,000 international units/mL) 4 times daily, metoclopramide 20 mg rectally 3 times daily, lidocaine oral spray, and lactulose.
Two weeks after the fentaNYL increase to 150 mcg/hr, he underwent a percutaneous gastrostomy because of worsening dysphagia. Eight days later he developed an oral fungal infection and was started on oral fluconazole 50 mg/day.
Three days after that, he died in his sleep. Forensic analysis showed a toxic fentaNYL concentration (0.017 mcg/g), high concentrations of fluconazole (2.4 mcg/g), lidocaine (1.6 mcg/g), and metoclopramide (0.15 mcg/g), and a therapeutic zolpidem concentration.
No evidence of ethanol or drugs of abuse was found. The only autopsy findings of note were pulmonary congestion and brain edema. There was no indication of intentional overdose, and the coroner determined that the cause of death was and circulatory failure due to fentaNYL intoxication.6
-
Report 5 · Study title
Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl
In an open, randomized, crossover study, giving voriconazole with a single IV dose of fentaNYL raised the mean of fentaNYL 1.4-fold and lowered the mean plasma by 23%. Twelve healthy volunteers received a single IV dose of fentaNYL 5 mcg/kg, either alone (control phase) or 1 hour after the last voriconazole dose on day 2 (400 mg orally twice daily on day 1, then 200 mg orally twice daily on day 2).
Naloxone was given before and with the fentaNYL dose to prevent the sedative and respiratory depressant effects of fentaNYL. All 12 subjects completed the study.
In the voriconazole phase, the mean AUC (0 to infinity) of fentaNYL was 1.4-fold higher (range, 0.81- to 2.04-fold) and the mean plasma clearance was 23% lower (range -22% to 48%) than in the control phase. Of note, the mean fentaNYL at 12 hr in the voriconazole phase was equal to that at 6 hr in the control phase.
Mean of fentaNYL again did not differ between the phases. Nausea and vomiting occurred in 4 subjects in the voriconazole phase and 2 subjects in the control phase. No additional naloxone doses were needed, and no other adverse events were reported.5
-
Report 6 · Study title
Prescribing information: Fentanyl citrate intravenous, intramuscular injection, fentanyl citrate intravenous, intramuscular injection
Observational studies have shown that using analgesics together with raises the risk of drug-related mortality relative to opioid analgesics used alone. Given their similar pharmacological properties, a comparable risk can reasonably be expected when other depressant drugs are used concomitantly with opioid analgesics.321
Fentanyl and Esketamine: Common Questions
How serious is the Fentanyl and Esketamine interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How is the Fentanyl and Esketamine interaction managed?
Do not stop or change either medicine on your own. Your care team can manage this combination, and they usually reserve it for people who do not have good alternatives. Your prescriber may use the lowest effective doses for the shortest time, and your fentanyl dose may need to be adjusted and individualized by your care team. Your team may monitor you more closely for sleepiness, slow breathing, l… Management is individual — always follow your own care team's guidance.
Is there an alternative to taking Fentanyl with Esketamine?
The interaction record says a different medicine may be considered in place of one of these two.
Only your prescriber can decide whether a change fits you, so talk with them before changing either medicine.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "established". Well documented — supported by controlled studies or strong clinical data.
Ask About the Fentanyl and Esketamine Interaction
Ask in your own words about taking Fentanyl and Esketamine together. The answer comes from this page’s interaction record and both drugs’ own information.
This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.
AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.
References (7)
- Product Information: FENTORA® buccal tablets, fentanyl citrate buccal tablets. Teva Pharmaceuticals USA Inc (per FDA), Parsippany, NJ, 2025.
- Product Information: ACTIQ® oral transmucosal lozenge, fentanyl citrate oral transmucosal lozenge. Teva Pharmaceuticals USA, Inc. (per FDA), Parsippany, NJ, 2025. DailyMed
- Product Information: Fentanyl citrate intravenous, intramuscular injection, fentanyl citrate intravenous, intramuscular injection. Rising Pharma Holdings, Inc. (per FDA), East Brunswick, NJ, 2025. DailyMed
- Olkkola KT, Palkama VJ, & Neuvonen PJ: Ritonavir's role in reducing fentanyl clearance and prolonging its half-life. Anesthesiology 1999; 91:681-685. PubMed
- Saari TI, Laine K, Neuvonen M, et al: Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl. Eur J Clin Pharmacol 2008; 64(1):25-30. PubMed
- Hallberg P, Marten L, & Wadelius M: Possible fluconazole-fentanyl interaction-a case report. Eur J Clin Pharmacol 2006; 62(6):491-492. PubMed
- Product Information: DIFLUCAN(R) oral tablets, suspension, fluconazole oral tablets, suspension. Roerig (per FDA), New York, NY, 2023. DailyMed
Other Serious Interactions of Fentanyl and Esketamine
Also serious with Esketamine
- IsocarboxazidContraindicated
- Acetaminophen and CodeineMajor
- BuprenorphineMajor
- Aripiprazole InjectionMajor
Also serious with Fentanyl
These Medications Also Interact With Supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
With Esketamine
- ScopoliaMajor
- YohimbeModerate
- DHEAModerate
- CowhageModerate
- Griffonia SimplicifoliaModerate
- Indian SnakerootModerate
- Rauvolfia VomitoriaModerate
- RhodiolaMinor
- + 3 more
With Fentanyl
- GrapefruitMajor
- St. John's WortMajor
- Activated CharcoalMajor
- KavaMajor
- WineMajor
- 1,4-butanediolMajor
- BeerMajor
- Gamma-hydroxybutyrate (GHB)Major
- + 222 more
Check everything you take with our drug–supplement interaction checker.
Still Have Questions About This Combination?
Every question gets a real answer from a licensed pharmacist — free, as soon as they can.
About This Library
Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →
What Each Rating Means
Severity Levels
- Contraindicated These should generally not be used together.
- Major Potentially serious — often needs a change or close monitoring. This interaction.
- Moderate Can be significant — usually manageable with monitoring.
- Minor Usually limited clinical impact.
Evidence Grades
- EstablishedWell documented — supported by controlled studies or strong clinical data. This interaction.
- ProbableGood supporting evidence, though not definitively proven.
- SuspectedSome evidence suggests this interaction, but it is not well established.
- PossibleLimited or conflicting evidence; the interaction may occur.
- TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.
How Soon It Shows
- RapidEffects can appear quickly, often within about 24 hours of combining the drugs.
- DelayedEffects tend to build up gradually over days to weeks.
- UnspecifiedThe timing of this interaction is not well characterized. This interaction.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.